A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox
(Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal
cancer. Patients will receive 6 x 21 day cycles of treatment with Avastin (7.5mg/kg iv on day
1), Xeloda (1000mg/m2 po twice daily on days 1 to 14) and Eloxatin (130mg/m2 iv on day 1).
Patients free of disease progression will then continue with Avastin (7.5mg/kg iv once every
3 weeks) and Tarceva (150mg po daily). The anticipated time on study treatment is until
disease progression, and the target sample size is <100 individuals.